PACB
Pacific Biosciences of California
2.30$
-15.4%
vs. previous close
Closing price · As of: Oct 8, 2026
Statements
Balance Sheet
All figures as a percentage of total assets in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 46.5% | 42.5% | 40.5% | 41.6% | 40.3% | 39.3% | 51.7% | 50.1% | 49.1% | 47.8% | 47.2% | 45.0% | |
| 20.3% | 10.3% | 4.6% | 6.6% | 5.4% | 4.4% | 6.8% | 6.6% | 7.0% | 8.1% | 7.2% | 8.1% | |
| 40.4% | 36.2% | 33.6% | 33.8% | 32.5% | 30.9% | 39.9% | 38.1% | 37.2% | 35.6% | 35.3% | 31.5% | |
| 1.6% | 2.1% | 1.8% | 2.1% | 2.0% | 2.2% | 3.7% | 3.9% | 3.8% | 4.5% | 3.8% | 4.1% | |
| 3.6% | 3.2% | 4.0% | 4.5% | 4.5% | 4.7% | 6.3% | 6.5% | 6.6% | 6.3% | 6.5% | 8.1% | |
| 24.4% | 26.5% | 27.7% | 24.4% | 25.5% | 25.2% | 36.9% | 38.5% | 39.6% | 40.5% | 40.6% | 42.3% | |
| 24.3% | 26.2% | 27.0% | 29.4% | 30.1% | 30.9% | 2.1% | 2.1% | 2.0% | 1.9% | 1.8% | 1.7% | |
| 59.8% | 59.8% | 61.1% | 67.4% | 68.8% | 59.8% | 89.4% | 92.6% | 95.5% | 99.3% | 99.7% | 104.4% | |
| 9.7% | 5.4% | 4.4% | 5.2% | 4.1% | 5.3% | 7.7% | 7.2% | 7.9% | 6.9% | 8.4% | 9.2% | |
| 0.5% | 0.6% | 0.6% | 0.8% | 0.7% | 0.8% | 0.3% | 0.1% | 0.5% | 0.1% | 0.0% | 0.2% | |
| 0.8% | 0.9% | 1.3% | 1.2% | 0.8% | 1.3% | 1.6% | 1.8% | 2.0% | 2.6% | 1.7% | 2.6% | |
| 47.0% | 51.1% | 53.4% | 59.1% | 61.6% | 51.4% | 75.1% | 78.3% | 80.3% | 82.3% | 82.3% | 85.7% | |
| 40.2% | 40.2% | 38.9% | 32.6% | 31.2% | 40.2% | 10.6% | 7.4% | 4.5% | 0.7% | 0.3% | -4.4% | |
| -92.6% | -105.3% | -114.8% | -138.5% | -148.4% | -170.5% | -299.1% | -317.0% | -330.6% | -343.8% | -345.6% | -365.5% | |
| 13.4% | 15.3% | 16.1% | 18.0% | 18.8% | 24.3% | 34.5% | 36.4% | 37.5% | 38.5% | 39.1% | 41.3% |
Data as of: October 8, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.